4 Stocks Pushing The Drugs Industry Downward

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Two out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 60 points (0.4%) at 15,029 as of Tuesday, May 7, 2013, 12:54 PM ET. The NYSE advances/declines ratio sits at 1,907 issues advancing vs. 994 declining with 159 unchanged.

The Drugs industry currently sits down 0.07 versus the S&P 500, which is up 0.3%. On the negative front, top decliners within the industry include Biogen Idec ( BIIB), down 0.62, and AstraZeneca ( AZN), down 0.46.

TheStreet Ratings group would like to highlight 4 stocks pushing the industry lower today:

4. Grifols ( GRFS) is one of the companies pushing the Drugs industry lower today. As of noon trading, Grifols is down $1.13 (-3.9%) to $28.12 on heavy volume Thus far, 2.3 million shares of Grifols exchanged hands as compared to its average daily volume of 352,100 shares. The stock has ranged in price between $27.44-$28.44 after having opened the day at $28.43 as compared to the previous trading day's close of $29.25.

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, and Canada. Grifols has a market cap of $16.6 billion and is part of the health care sector. Shares are up 15.1% year to date as of the close of trading on Monday.

TheStreet Ratings rates Grifols as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Grifols Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you liked this article you might like

Hologic Agrees to Sell Blood Screening Business to Grifols for $1.85B

5 Big Dividend Stocks Billionaire John Paulson Loves

3 Stocks Pulling The Health Services Industry Downward

3 Stocks Pushing The Health Services Industry Higher

3 Health Services Stocks Driving The Industry Higher